Skip to main content

Table 4 Correlation of serum levels and activity of MPO with plaque progression in patients with type 2 diabetes

From: Serum MPO levels and activities are associated with angiographic coronary atherosclerotic plaque progression in type 2 diabetic patients

 

Changes in MLD

Changes in stenosis diameter

Changes in CCSS

Serum levels of MPO, ng/mL

 Unadjusted r

0.62

 − 0.62

 − 0.59

 Unadjusted P

< 0.001

 < 0.001

 < 0.001

 Adjusted r*

0.53

 − 0.44

 − 0.56

 Adjusted P*

< 0.001

 < 0.001

 < 0.001

Serum MPO activity, mU/mL

 Unadjusted r

0.38

 − 0.37

 − 0.38

 Unadjusted P

< 0.001

 < 0.001

 < 0.001

 Adjusted r*

0.30

 − 0.31

 − 0.33

 Adjusted P*

< 0.001

 < 0.001

 < 0.001

  1. Change of QCA measurement is defined as baseline QCA measurement minus follow-up measurement
  2. CRP C-reactive protein, HDL High-density lipoprotein, LDL Low-density lipoprotein, CCSS Cumulative coronary stenosis score, MLD Minimal lumen diameter, QCA Quantitative coronary analyses
  3. *Adjusted for gender, age, body mass index, history of hypertension, smoking, glycated hemoglobin A1c, estimated glomerular filtration rate, HDL cholesterol, LDL cholesterol, Log CRP, antiplatelet and statins use